Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: H02AB09

Efmody(hydrocortisone)

Adrenal Hyperplasia, Congenital

Marketing Authorisation Holder: Immedica Pharma AB

EMA Authorisation: 27/05/2021

INN: hydrocortisone

Indication

Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Efmody — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.